2024
Early Disease-Modifying Treatments for Presymptomatic Multiple Sclerosis
Zeydan B, Azevedo C, Makhani N, Cohen M, Tutuncu M, Thouvenot E, Siva A, Okuda D, Kantarci O, Lebrun-Frenay C. Early Disease-Modifying Treatments for Presymptomatic Multiple Sclerosis. CNS Drugs 2024, 1-11. PMID: 39285136, DOI: 10.1007/s40263-024-01117-9.Peer-Reviewed Original ResearchRadiologically isolated syndromeRisk factorsLaboratory biomarkersMultiple sclerosisDisease-modifying treatmentsSpinal cordGadolinium-enhancing lesionsEfficacy of disease-modifying treatmentsRandomized clinical trialsIncrease diagnostic accuracyLack of clinical guidelinesSymptomatic MSNeurofilament-light chainCSF abnormalitiesPresymptomatic individualsAdverse eventsMale sexMS criteriaClinical eventsDiagnostic accuracyClinical trialsDisease outcomeClinical guidelinesYounger ageLesions
2018
1901. Safety, Tolerability, and Efficacy of Fluoxetine as an Antiviral for Enterovirus D68 Associated Acute Flaccid Myelitis: A Retrospective Multicenter Cohort Study
Messacar K, Sillau S, Hopkins S, Otten C, Wilson-Murphy M, Wong B, Santoro J, Treister A, Tokhie H, Torres A, Zabrocki L, Glanternik J, Hurst A, Martin J, Schreiner T, Makhani N, DeBiasi R, Kruer M, Tremoulet A, Van Haren K, Desai J, Benson L, Gorman M, Abzug M, Tyler K, Dominguez S. 1901. Safety, Tolerability, and Efficacy of Fluoxetine as an Antiviral for Enterovirus D68 Associated Acute Flaccid Myelitis: A Retrospective Multicenter Cohort Study. Open Forum Infectious Diseases 2018, 5: s546-s546. PMCID: PMC6254028, DOI: 10.1093/ofid/ofy210.1557.Peer-Reviewed Original ResearchAcute flaccid myelitisFluoxetine-treated patientsSerious adverse eventsMulticenter cohort studyEfficacy of fluoxetineEV-D68Cohort studyInitial examinationSevere paralysisRetrospective multicenter cohort studyPoor long-term outcomesAdverse effectsDose of fluoxetinePropensity-adjusted analysisLong-term disabilityLong-term outcomesPotential antiviral therapiesUntreated controlsAdverse eventsMost patientsEfficacy signalsPrimary outcomeAntiviral therapyStudy criteriaEffective therapySafety, tolerability, and efficacy of fluoxetine as an antiviral for acute flaccid myelitis
Messacar K, Sillau S, Hopkins SE, Otten C, Wilson-Murphy M, Wong B, Santoro JD, Treister A, Bains HK, Torres A, Zabrocki L, Glanternik JR, Hurst AL, Martin JA, Schreiner T, Makhani N, DeBiasi RL, Kruer MC, Tremoulet AH, Van Haren K, Desai J, Benson LA, Gorman MP, Abzug MJ, Tyler KL, Dominguez SR. Safety, tolerability, and efficacy of fluoxetine as an antiviral for acute flaccid myelitis. Neurology 2018, 92: e2118-e2126. PMID: 30413631, PMCID: PMC6512883, DOI: 10.1212/wnl.0000000000006670.Peer-Reviewed Original ResearchConceptsAcute flaccid myelitisSerious adverse eventsFluoxetine-treated patientsEfficacy of fluoxetineEV-D68Initial examinationPoor long-term outcomesImproved neurologic outcomeMulticenter cohort studyClass IV evidenceAdverse effect ratesDose of fluoxetinePropensity-adjusted analysisLong-term outcomesUnexposed patientsNeurologic outcomeUntreated patientsAdverse eventsCohort studyPrimary outcomeUS patientsStudy criteriaEnterovirus D68PatientsEffect rate